Abstract
The original description of endothelin-1 (ET-1) included the concept that a novel processing enzyme, referred to as endothelin-converting enzyme (ECE), was required for cleavage of the Trp21–Val22 bond in the biosynthetic intermediate big ET-1 (1). Initially it was thought that ECE could be a chymotrypsinlike enzyme because of the nature of the peptide bond being cleaved (1). The challenge of identifying ECE was soon taken up by many groups and a variety of different proteolytic activities were proposed as potential ECEs (2). By 1990, studies of endogenous ET-1 synthesis by cultured endothelial cells and investigations of the systemic pressor effect of intravenously administered big ET-1 indicated that the physiological ECE was a phosphoramidon-sensitive enzyme (3–5). Phosphoramidon was also shown to inhibit hydrolysis of exogenous big ET-1 by cultured vascular smooth muscle and endothelial cells (6). The pursuit of an ECE that could selectively hydrolyze big ET-1 and was inhibited by phosphoramidon led quickly to the purification and cloning of a metallopeptidase called endothelin-converting enzyme-1 (ECE-1) (7–9). Shortly after this, a second phosphoramidon-sensitive peptidase, with ∼59% structural homology to ECE-1, was cloned and called ECE-2 (10). ECE-1 and ECE-2 are members of a family of type II integral membrane peptidases that also includes neutral endopeptidase 24.11 and the KELL and PEX proteins (11).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., et al. (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411–415.
Opgenorth T. J., Wu-Wong J. R., and Shiosaki K. (1992) Endothelin-converting enzymes. FASEB J. 6, 2653–2659.
Fukuroda T., Noguchi K., Tsuchida S., Nishikibe M., Ikemoto F., Okada K., and Yano M. (1990) Inhibition of biological actions of big endothelin-1 by phosphoramidon. Biochem. Biophys. Res. Commun. 172, 390–395.
Ikegawa R., Matsumura Y., Tsukahara Y., Takaoka M., and Morimoto S. (1990) Phosphoramidon, a metalloproteinase inhibitor, suppresses the secretion of endothelin-1 from cultured endothelial cells by inhibiting a big endothelin-1 converting enzyme. Biochem. Biophys. Res. Commun. 171, 669–675.
Matsumura Y., Hisaki K., Takaoka M., and Morimoto S. (1990) Phosphoramidon, a metalloproteinase inhibitor, suppresses the hypertensive effect of big endothelin-1. Eur. J. Pharmacol. 185, 103–106.
Ikegawa R., Matsumura Y., Tsukahara Y., Takaoka M., and Morimoto S. (1991) Phosphoramidon inhibits the generation of endothelin-1 from exogenously applied big endothelin-1 in cultured vascular endothelial cells and smooth muscle cells. FEBS Letts. 293, 45–48.
Schmidt M., Kroger B., Jacob E., Seulberger H., Subkowski T., Otter R., et al. (1994) Molecular characterization of human and bovine endothelin converting enzyme (ECE-1). FEBS Letts. 356, 238–243.
Shimada K., Takahashi M., and Tanzawa K. (1994) Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J. Biol. Chem. 269, 18,275–18,278.
Xu D., Emoto N., Giaid A., Slaughter C., Kaw S., deWit D., and Yanagisawa M. (1994) ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 78, 473–485.
Emoto N. and Yanagisawa M. (1995) Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J. Biol. Chem. 270, 15,262–15,268.
Turner A. J. and Tanzawa K. (1997) Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J. 11, 355–364.
Valdenaire O., Rohrbacher E., and Mattei M. G. (1995) Organization of the gene encoding the human endothelin-converting enzyme (ECE-1). J. Biol. Chem. 270, 29,794–29,798.
Valdenaire O., Lepailleur-Enouf D., Egidy G., Thouard A., Barret A., Vranckx R., et al. (1999) A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter. Molecular cloning and characterization. Eur. J. Biochem. 264, 341–349.
Corder R. (2001) Identity of endothelin-converting enzyme and other targets forthe therapeutic regulation of endothelin biosynthesis. In Handbook of Experimental Pharmacology, vol. 152 (ieWarner T. D., ed.), Springer-Verlag, pp. 36–67.
Barker S., Khan N. Q., Wood E. G., and Corder R. (2001) Effect of an antisense oligodeoxynucleotide to endothelin-converting enzyme-1c (ECE-1c) on ECE-1c mRNA, ECE-1 protein and endothelin-1 synthesis in bovine pulmonary artery smooth muscle cells. Mol. Pharmacol. 59, 163–169.
Korth P., Bohle R. M., Corvol P., and Pinet F. (1999) Cellular distribution of endothelin-converting enzyme-1 in human tissues. J. Histochem. Cytochem. 47, 447–461.
Schweizer A., Valdenaire O., Nelbock P., Deuschle U., Dumas Milne Edwards J. B., Stumpf J. G., and Löffler B. M. (1997) Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations. Biochem. J. 328, 871–877.
Corder R. and Barker S. (1999) The expression of endothelin-1 and endothelinconvertingenzyme-1 (ECE-1) are independently regulated in bovine aortic endothelial cells. J. Cardiovasc. Pharmacol 33, 671–677.
Barnes K., Brown C., and Turner A. J. (1998) Endothelin-converting enzyme: ultrastructural localization and its recycling from the cell surface. Hypertension 31, 3–9.
Grantham J. A., Schirger J. A., Williamson E. E., Heublein D. M., Wennberg P. W., Kirchengast M., Muenter K., Subkowski T., and Burnett J. C. (1998) Enhanced endothelin-converting enzyme immunoreactivity in early atherosclerosis. J. Cardiovasc. Pharmacol. 31Suppl 1), S22–S26.
Minamino T., Kurihara H., Takahashi M., Shimada K., Maemura K., Oda H., et al. (1997) Endothelin-converting enzyme expression in the rat vascular injury model and human coronary atherosclerosis. Circulation 95, 221–230.
Wang X., Douglas S. A., Louden C., Vickery-Clark L. M., Feuerstein G. Z., and Ohlstein E. H. (1996) Expression of endothelin-1, endothelin-3, endothelinconverting enzyme-1, and endothelin-A and endothelin-B receptor mRNA after angioplasty-induced neointimal formation in the rat. Circ. Res. 78, 322–328.
Harrison V.J., Barnes K., Turner A.J., Wood E., Corder R., and Vane J. R. (1995) Identification of endothelin 1 and big endothelin 1 in secretory vesicles isolated from bovine aortic endothelial cells. Proc. Natl. Acad. Sci. USA 92, 6344–6348.
Takahashi M., Fukuda K., Shimada K., Barnes K., Turner A. J., et al. (1995) Localization of rat endothelin-converting enzyme to vascular endothelial cells and some secretory cells. Biochem. J. 311, 657–665.
Russell F. D., Skepper J. N., and Davenport A. P. (1998) Human endothelial cell storage granules. A novel intracellular site for isoforms of the endothelinconverting enzyme. Circ. Res. 83, 314–321.
Brown C.D., Barnes K., and Turner A. J. (1998) Anti-peptide antibodies specific to rat endothelin-converting enzyme-1 isoforms reveal isoform localisation and expression. FEBS Letts. 424, 183–187.
Azarani A., Boileau G., and Crine P. (1998) Recombinant human endothelin-converting enzyme ECE-1b is located in an intracellular compartment when expressed in polarized Madin-Darby canine kidney cells. Biochem. J. 333, 439–448.
Schweizer A., Löffler B. M., and Rohrer J. (1999) Palmitoylation of the threeisoforms of human endothelin-converting enzyme-1. Biochem. J. 340, 649–656.
Yanagisawa H., Yanagisawa M., Kapur R. P., Richardson J. A., Williams S.C., Clouthier D. E., et al. (1998) Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. Development 125, 825–836.
Bustin S. A. (2000) Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 25, 169–193.
Lambert G. L., Barker S., Lees D. M., and Corder R. (2000) Endothelin-2synthesis is stimulated by the type-1 tumour necrosis factor receptor and cAMP: comparison with endothelin-converting enzyme-1 expression. J. Mol. Endocrinol 24, 273–283.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Humana Press Inc.
About this protocol
Cite this protocol
Lees, D.M., Khan, N.Q., Barker, S., Corder, R. (2002). Quantitative Measurement of mRNA Levels by RT-PCR. In: Maguire, J.J., Davenport, A.P. (eds) Peptide Research Protocols. Methods in Molecular Biology™, vol 206. Springer, Totowa, NJ. https://doi.org/10.1385/1-59259-289-9:125
Download citation
DOI: https://doi.org/10.1385/1-59259-289-9:125
Publisher Name: Springer, Totowa, NJ
Print ISBN: 978-0-89603-993-3
Online ISBN: 978-1-59259-289-0
eBook Packages: Springer Protocols